Seroatlas · Human Serome Atlas

NRXN2

Neurexin-2

Also known as: NRX2A_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9P2S2
Gene
NRXN2
Ensembl
ENSG00000110076
Chromosome
11
Canonical length
1712 aa
Protein class
Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

This gene encodes a member of the neurexin gene family. The products of these genes function as cell adhesion molecules and receptors in the vertebrate nervous system. These genes utilize two promoters. The majority of transcripts are produced from the upstream promoter and encode alpha-neurexin isoforms while a smaller number of transcripts are produced from the downstream promoter and encode beta-neuresin isoforms. The alpha-neurexins contain epidermal growth factor-like (EGF-like) sequences and laminin G domains, and have been shown to interact with neurexophilins. The beta-neurexins lack EGF-like sequences and contain fewer laminin G domains than alpha-neurexins. Alternative splicing and the use of alternative promoters may generate thousands of transcript variants (PMID: 12036300, PMID: 11944992).[provided by RefSeq, Jun 2010]

Canonical amino-acid sequenceUniProt

1712 residues, UniProt reviewed canonical sequence.

>Q9P2S2|NRXN2
     1  MASGSRWRPT PPPLLLLLLL ALAARADGLE FGGGPGQWAR YARWAGAASS GELSFSLRTN
    61  ATRALLLYLD DGGDCDFLEL LLVDGRLRLR FTLSCAEPAT LQLDTPVADD RWHMVLLTRD
   121  ARRTALAVDG EARAAEVRSK RREMQVASDL FVGGIPPDVR LSALTLSTVK YEPPFRGLLA
   181  NLKLGERPPA LLGSQGLRGA TADPLCAPAR NPCANGGLCT VLAPGEVGCD CSHTGFGGKF
   241  CSEEEHPMEG PAHLTLNSEV GSLLFSEGGA GRGGAGDVHQ PTKGKEEFVA TFKGNEFFCY
   301  DLSHNPIQSS TDEITLAFRT LQRNGLMLHT GKSADYVNLS LKSGAVWLVI NLGSGAFEAL
   361  VEPVNGKFND NAWHDVRVTR NLRQHAGIGH AMVNKLHYLV TISVDGILTT TGYTQEDYTM
   421  LGSDDFFYIG GSPNTADLPG SPVSNNFMGC LKDVVYKNND FKLELSRLAK EGDPKMKLQG
   481  DLSFRCEDVA ALDPVTFESP EAFVALPRWS AKRTGSISLD FRTTEPNGLL LFSQGRRAGG
   541  GAGSHSSAQR ADYFAMELLD GHLYLLLDMG SGGIKLRASS RKVNDGEWCH VDFQRDGRKG
   601  SISVNSRSTP FLATGDSEIL DLESELYLGG LPEGGRVDLP LPPEVWTAAL RAGYVGCVRD
   661  LFIDGRSRDL RGLAEAQGAV GVAPFCSRET LKQCASAPCR NGGVCREGWN RFICDCIGTG
   721  FLGRVCEREA TVLSYDGSMY MKIMLPNAMH TEAEDVSLRF MSQRAYGLMM ATTSRESADT
   781  LRLELDGGQM KLTVNLDCLR VGCAPSKGPE TLFAGHKLND NEWHTVRVVR RGKSLQLSVD
   841  NVTVEGQMAG AHMRLEFHNI ETGIMTERRF ISVVPSNFIG HLSGLVFNGQ PYMDQCKDGD
   901  ITYCELNARF GLRAIVADPV TFKSRSSYLA LATLQAYASM HLFFQFKTTA PDGLLLFNSG
   961  NGNDFIVIEL VKGYIHYVFD LGNGPSLMKG NSDKPVNDNQ WHNVVVSRDP GNVHTLKIDS
  1021  RTVTQHSNGA RNLDLKGELY IGGLSKNMFS NLPKLVASRD GFQGCLASVD LNGRLPDLIA
  1081  DALHRIGQVE RGCDGPSTTC TEESCANQGV CLQQWDGFTC DCTMTSYGGP VCNDPGTTYI
  1141  FGKGGALITY TWPPNDRPST RMDRLAVGFS THQRSAVLVR VDSASGLGDY LQLHIDQGTV
  1201  GVIFNVGTDD ITIDEPNAIV SDGKYHVVRF TRSGGNATLQ VDSWPVNERY PAGNFDNERL
  1261  AIARQRIPYR LGRVVDEWLL DKGRQLTIFN SQAAIKIGGR DQGRPFQGQV SGLYYNGLKV
  1321  LALAAESDPN VRTEGHLRLV GEGPSVLLSA ETTATTLLAD MATTIMETTT TMATTTTRRG
  1381  RSPTLRDSTT QNTDDLLVAS AECPSDDEDL EECEPSTGGE LILPIITEDS LDPPPVATRS
  1441  PFVPPPPTFY PFLTGVGATQ DTLPPPAARR PPSGGPCQAE RDDSDCEEPI EASGFASGEV
  1501  FDSSLPPTDD EDFYTTFPLV TDRTTLLSPR KPAPRPNLRT DGATGAPGVL FAPSAPAPNL
  1561  PAGKMNHRDP LQPLLENPPL GPGAPTSFEP RRPPPLRPGV TSAPGFPHLP TANPTGPGER
  1621  GPPGAVEVIR ESSSTTGMVV GIVAAAALCI LILLYAMYKY RNRDEGSYQV DQSRNYISNS
  1681  AQSNGAVVKE KAPAAPKTPS KAKKNKDKEY YV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NRXN2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.37
Highest tissue expression
185 nTPM

Expression across tissuesHPA

Tissue

  • cerebellum: 185 nTPM
  • cerebral cortex: 90 nTPM
  • amygdala: 76 nTPM
  • hypothalamus: 59 nTPM
  • hippocampal formation: 59 nTPM
  • basal ganglia: 48 nTPM

Single-cell type

  • retinal amacrine cells: 220 nCPM
  • oligodendrocyte progenitor cells: 121 nCPM
  • retinal horizontal cells: 118 nCPM
  • brain excitatory neurons: 112 nCPM
  • early primary spermatocytes: 108 nCPM
  • brain inhibitory neurons: 81 nCPM

Immune cell

  • intermediate monocyte: 0.4 nTPM
  • non-classical monocyte: 0.3 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM

Brain region

  • cerebellum: 441 nTPM
  • amygdala: 345 nTPM
  • cerebral cortex: 342 nTPM
  • basal ganglia: 312 nTPM
  • hippocampal formation: 261 nTPM
  • thalamus: 255 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NRXN2.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 356 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • NRXN2-related developmental disorder

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.26
gnomAD pLI
1
gnomAD missense Z
4.02
DepMap mean gene effect
-0.01
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NRXN2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NRXN2 as an antibody target. Whether an autoantibody or antibody against NRXN2 could matter depends on whether native NRXN2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NRXN2 is annotated at the cell surface, where native NRXN2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label NRXN2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/NRXN2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...